Zoetis Scientists Present Positive Efficacy Data for Investigational Triple Combination Parasiticide at American Heartworm Society Meeting
Triple combination product contains sarolaner, moxidectin and pyrantel
The results from effectiveness studies in dogs treated with the combination product demonstrated that no adult heartworms were recovered from animals in the laboratory studies and no positive test results for adult heartworms were obtained from dogs in the field study. The product was well-tolerated in all studies presented.
In addition, data from a separate study, which tested the efficacy of oral moxidectin at doses ranging from 3 to 60 µg/kg against three confirmed macrocyclic lactone resistant heartworm strains, served as the basis for selecting the dose of moxidectin included in the investigational combination product. In this study, moxidectin at 24µg/kg given monthly for three consecutive months demonstrated a high level of efficacy in reducing the development of heartworms in these dogs.
The abstracts are available to conference attendees only at this time, but
As previously disclosed in its second quarter earnings, Zoetis’ combination parasiticide product is in regulatory review in the U.S.,
About Heartworm Disease
Canine heartworm disease is a serious, potentially fatal condition that can result in severe lung disease, heart failure and damage to other internal organs. The disease is caused by a filarial parasite, Dirofilaria immitis, which is transmitted to dogs though the bite of an infected mosquito. Adult worms live in the heart, lungs and associated blood vessels of an infected animal (7).
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of
References (as of
- Pulaski CN, Malone JB, Bourguinat C, Prichard R, Geary T, Ward DR, et al. Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally infected laboratory dogs. Parasit Vectors. 2014;7:494.
- Bourguinat C, Lee A, Lizunda R, Blagburn B, Liotta J, Kraus M, et al. Macrocyclic lactone resistance in Dirofilaria immitis: failure of heartworm preventives and investigation of genetic markers for resistance. Vet Parasitol. 2015:210;167–78.
- Maclean MJ, Savadelis MD, Coates R, Dzimianski M, Jones C, Benbow C, et al. Does evaluation of in vitro microfiliarial motility reflect the resistance status of Dirofilaria immitis isolates to macrocyclic lactones? Parasit Vectors. 2017:10(Suppl. 2);480.
- Blagburn BL, Arther RG, Dillon AR, Butler JM, Bowles JV, von Simpson C, Zolynas R. Efficacy of four commercially available heartworm preventive products against the JYD-34 laboratory strain of Dirofilaria immitis. Parasit Vectors. 2016:9;191.
- McTier TL, Six RH, Pullins A, Chapin S, McCall JW, Rugg D, et al. Efficacy of oral moxidectin against susceptible and resistant isolates of Dirofilaria immitis in dogs. Parasit Vectors. 2017:10(Suppl. 2);482.
- Ballesteros C, Pulaski C N, Bourguinat C, Keller K, Prichard RK, Geary TG. Clinical validation of molecular markers of macrocyclic lactone resistance in Dirofilaria immitis. Int J Parasitol Drugs Drug Resist. 2018;8:596–606.
- www.fda.gov/animal-veterinary-literacy/keep-worms-out -your pets-heart-facts-about-heartworm-disease